Quest Diagnostics Incorporated (DGX)

Market Cap	15.18B
Revenue (ttm)	9.29B
Net Income (ttm)	846.00M
Shares Out	111.09M
EPS (ttm)	7.43
PE Ratio	18.39
Forward PE	15.08
Dividend	$3.00 (2.20%)
Ex-Dividend Date	Jul 8, 2024

Volume	982,210
Open	137.06
Previous Close	137.09
Day's Range	136.35 - 138.05
52-Week Range	119.59 - 145.62
Beta	0.89
Analysts	Buy
Price Target	148.25 (+8.5%)
Earnings Date	Jul 23, 2024

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, govern...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 48,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX

Financial Performance

In 2023, DGX's revenue was $9.25 billion, a decrease of -6.38% compared to the previous year's $9.88 billion. Earnings were $854.00 million, a decrease of -9.73%.

Analyst Forecast

According to 12 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $148.25, which is an increase of 8.50% from the latest price.

Price Target

$148.25

(8.50% upside)

Analyst Consensus: Buy